

AmeriHealth Caritas Pennsylvania Community Health Choices

Specifications for Gaps in Care

Dyslipidemia – Lipid Lowering Therapy

Purpose: The purpose of this measure is to identify and track members who are diagnosed with dyslipidemia and are not filling lipid lowering medications

Who is Included? (denominator)	<ul style="list-style-type: none"> o Members diagnosed with dyslipidemia (272.xx) <p>Exclusion: members < 10 years old</p>
What Pharmacy Claim Data is evaluated? (numerator)	<ul style="list-style-type: none"> o Claims for lipid lowering agents (single and multi-ingredient products containing: statins, niacin, bile acid sequestrants, cholesterol absorption inhibitors, omega 3 fatty acids, or fibric acids)
When does the analysis occur?	<ul style="list-style-type: none"> o Reviews claims from the previous 3 months o Updated Monthly
Where can I get this information?	<ul style="list-style-type: none"> o Monthly NaviNet report updates reflect Gaps In Care for PCP practice panel membership. o Quarterly printed reports sent to PCPs reflect Gaps In Care for PCP practice panel membership. o Panel membership results include indicators for this Gaps In Care measure as “At Risk”
Why does my member have an “At Risk” status?	<ul style="list-style-type: none"> o Pharmacy claims show a failure to fill a lipid lowering agent in the previous 3 months

Reference: Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP). JAMA. 2001;285(19):2486-97.

Revised: October 2017